Compass Capital Management Inc. Has $61.63 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Compass Capital Management Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 371,633 shares of the company’s stock after purchasing an additional 3,595 shares during the period. Johnson & Johnson makes up approximately 4.1% of Compass Capital Management Inc.’s investment portfolio, making the stock its 12th largest holding. Compass Capital Management Inc.’s holdings in Johnson & Johnson were worth $61,632,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. MRP Capital Investments LLC grew its stake in shares of Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock worth $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co increased its holdings in shares of Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock worth $202,000 after acquiring an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management increased its holdings in shares of Johnson & Johnson by 3.3% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after acquiring an additional 66 shares in the last quarter. Denali Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after acquiring an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after acquiring an additional 67 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on JNJ shares. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays lowered their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Up 0.2%

JNJ stock opened at $156.90 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $377.52 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. The business has a 50 day moving average price of $153.84 and a two-hundred day moving average price of $153.70. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.